Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol; Sarah Lévesque; Samuel T. Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R. Clements; Jean Eudes Fahrner; Laetitia Fend; John C. Bell; Karen L. Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1503032

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

68 Citations (Scopus)

Résumé

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

langue originale	Anglais
Numéro d'article	e1503032
journal	OncoImmunology
Volume	7
Numéro de publication	12
Les DOIs	https://doi.org/10.1080/2162402X.2018.1503032
état	Publié - 2 déc. 2018

Accès au document

10.1080/2162402X.2018.1503032

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

G. Pol, J., Lévesque, S., Workenhe, S. T., Gujar, S., Le Boeuf, F., R. Clements, D., Fahrner, J. E., Fend, L., C. Bell, J., L. Mossman, K., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018). Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 7(12), Article e1503032. https://doi.org/10.1080/2162402X.2018.1503032

@article{8d1dc977c6eb4d3dbd184d7317c692eb,

title = "Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors",

abstract = "Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.",

keywords = "CAVATAK, DNX-2401, HF10, MV-NIS, Maraba MG1, Pexa-Vec, REOLYSIN, T-VEC",

author = "{G. Pol}, Jonathan and Sarah L{\'e}vesque and Workenhe, {Samuel T.} and Shashi Gujar and {Le Boeuf}, Fabrice and {R. Clements}, Derek and Fahrner, {Jean Eudes} and Laetitia Fend and {C. Bell}, John and {L. Mossman}, Karen and Jitka Fucikova and Radek Spisek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/2162402X.2018.1503032",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

number = "12",

}

TY - JOUR

T1 - Trial Watch

T2 - Oncolytic viro-immunotherapy of hematologic and solid tumors

AU - G. Pol, Jonathan

AU - Lévesque, Sarah

AU - Workenhe, Samuel T.

AU - Gujar, Shashi

AU - Le Boeuf, Fabrice

AU - R. Clements, Derek

AU - Fahrner, Jean Eudes

AU - Fend, Laetitia

AU - C. Bell, John

AU - L. Mossman, Karen

AU - Fucikova, Jitka

AU - Spisek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

AB - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

KW - CAVATAK

KW - DNX-2401

KW - HF10

KW - MV-NIS

KW - Maraba MG1

KW - Pexa-Vec

KW - REOLYSIN

KW - T-VEC

UR - http://www.scopus.com/inward/record.url?scp=85058014194&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1503032

DO - 10.1080/2162402X.2018.1503032

M3 - Review article

C2 - 30524901

AN - SCOPUS:85058014194

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 12

M1 - e1503032

ER -